AR031828A2 - Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia - Google Patents
Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapiaInfo
- Publication number
- AR031828A2 AR031828A2 ARP000101632A ARP000101632A AR031828A2 AR 031828 A2 AR031828 A2 AR 031828A2 AR P000101632 A ARP000101632 A AR P000101632A AR P000101632 A ARP000101632 A AR P000101632A AR 031828 A2 AR031828 A2 AR 031828A2
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- enantiomer
- preparing
- spiro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 11
- 238000000034 method Methods 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 239000002253 acid Substances 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 230000002152 alkylating effect Effects 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Procedimientos para la preparacion de compuestos espiro-azabicíclicos que tienen la formula (1), donde R representa hidrogeno o metilo; y n representa 1 o 2; o una sal de adicion de ácido farmacéuticamente aceptable o de un enantiomero del mismo, que comprende (a) preparar un compuesto de formula (1) en el que R representa hidrogeno ciclando un correspondiente compuesto de formula (2), donde n es tal como se ha definido anteriormente; (b) preparar un compuesto de formula (1) mediante la reaccion de un compuesto correspondiente de formula (3), donde n y R son tal como se han definido anteriormente, con un compuesto dador de carbonilo; (c) preparar un compuesto de formula (1) donde R representa metilo mediante la alquilacion de un compuesto correspondiente de formula (1) en el que R representa hidrogeno; o (d) preparar un enantiomero de un compuesto de formula (1) resolviendo el enantiomero a partir de una mezcla de enantiomeros; y cuando se desea o es necesario convertir el compuesto resultante de formula (1), o una sal de adicion de ácido del mismo o un enantiomero del mismo a una sal de adicion de ácido farmacéuticamente aceptable o a un enantiomero del mismo, o viceversa; y procedimiento para preparar composiciones farmacéuticas utiles en terapia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9417084A GB9417084D0 (en) | 1994-08-24 | 1994-08-24 | Compounds useful in therapy |
| GBGB9504627.2A GB9504627D0 (en) | 1995-03-08 | 1995-03-08 | Compounds for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031828A2 true AR031828A2 (es) | 2003-10-08 |
Family
ID=26305509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000101632A AR031828A2 (es) | 1994-08-24 | 2000-04-10 | Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US5902814A (es) |
| EP (1) | EP0777671B1 (es) |
| JP (1) | JP3708962B2 (es) |
| KR (1) | KR100366331B1 (es) |
| CN (2) | CN1056846C (es) |
| AR (1) | AR031828A2 (es) |
| AT (1) | ATE192157T1 (es) |
| AU (1) | AU690735B2 (es) |
| BR (1) | BR9508751A (es) |
| CA (1) | CA2196995C (es) |
| CZ (1) | CZ289512B6 (es) |
| DE (1) | DE69516524T2 (es) |
| DK (1) | DK0777671T3 (es) |
| EE (1) | EE03399B1 (es) |
| EG (1) | EG24222A (es) |
| ES (1) | ES2145922T3 (es) |
| FI (1) | FI112868B (es) |
| GR (1) | GR3033878T3 (es) |
| HU (1) | HUT77352A (es) |
| IL (1) | IL115039A (es) |
| IS (1) | IS1852B (es) |
| MX (1) | MX9701292A (es) |
| NO (1) | NO307707B1 (es) |
| NZ (1) | NZ292289A (es) |
| PL (1) | PL183933B1 (es) |
| PT (1) | PT777671E (es) |
| RU (1) | RU2148058C1 (es) |
| SA (1) | SA95160370B1 (es) |
| SK (1) | SK282366B6 (es) |
| TR (1) | TR199501053A2 (es) |
| TW (1) | TW397837B (es) |
| UA (1) | UA54375C2 (es) |
| WO (1) | WO1996006098A1 (es) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| JP4564135B2 (ja) * | 1999-07-26 | 2010-10-20 | 住友化学株式会社 | 高純度フェノチアジン化合物とその製造方法、およびその中間体の製造方法、並びにその中間体の原料の水和物と新規結晶 |
| AU2001241056A1 (en) * | 2000-03-09 | 2001-09-17 | Mitsubishi Pharma Corporation | Spiro compounds, process for preparing the same and use thereof as drugs |
| US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| AU2001286938A1 (en) * | 2000-08-28 | 2002-03-13 | Colorado State University Research Foundation | Compounds containing oxazolidinone moiety and uses thereof |
| US6569865B2 (en) | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
| EP1453828A2 (en) * | 2001-10-16 | 2004-09-08 | AstraZeneca AB | Azabicyclic compounds for the treatment of fibromyalgia syndrome |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| CA2476896A1 (en) * | 2002-02-26 | 2003-09-04 | North Shore-Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
| SE0202598D0 (sv) * | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
| US7238715B2 (en) * | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| CN102657651A (zh) * | 2002-12-06 | 2012-09-12 | 范因斯坦医学研究院 | 用α 7受体结合胆碱能激动剂抑制炎症 |
| KR20060057569A (ko) * | 2003-07-08 | 2006-05-26 | 아스트라제네카 아베 | 알파7 니코틴계 아세틸콜린 수용체와 친화도를 갖는스피로[1-아자비시클로[2.2.2]옥탄-3,5'-옥사졸리딘-2'-온] 유도체 |
| CA2560756A1 (en) * | 2004-03-25 | 2005-10-06 | The Feinstein Institute For Medical Research | Methods and devices for reducing bleed time using vagus nerve stimulation |
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| US20080113983A1 (en) * | 2004-12-15 | 2008-05-15 | Astrazeneca Ab | Nicotinic Acetylcholine Receptor Ligands |
| DE602005025020D1 (de) | 2004-12-27 | 2011-01-05 | The Feinstein Inst Medical Res | Behandlung von entzündlichen erkrankungen durch el |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| JP2008525524A (ja) * | 2004-12-28 | 2008-07-17 | アストラゼネカ・アクチエボラーグ | アリールスルホンアミドモジュレーター |
| JP2009506069A (ja) * | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| RU2326787C2 (ru) * | 2005-11-09 | 2008-06-20 | Сергей Федорович Бокарев | Способ управления крылом, помещенным в текучую среду, при его взаимодействии с этой средой и устройство для его осуществления |
| US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| EP2255848A3 (en) | 2006-09-04 | 2011-04-06 | NeuroSearch AS | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| DE102008015999B4 (de) | 2008-03-27 | 2011-04-21 | Novar Gmbh | Übertragungsweg - Prüfverfahren für eine Gefahrenmeldeanlage |
| US9211409B2 (en) * | 2008-03-31 | 2015-12-15 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of T-cell activity |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| US7863291B2 (en) * | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| US8309577B2 (en) | 2008-04-23 | 2012-11-13 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
| KR20110019781A (ko) | 2008-06-20 | 2011-02-28 | 아스트라제네카 아베 | 디벤조티아제핀 유도체 및 그의 용도 |
| ES2452484T3 (es) | 2008-11-18 | 2014-04-01 | Setpoint Medical Corporation | Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria |
| CN105687190A (zh) | 2008-11-19 | 2016-06-22 | 福拉姆医药股份有限公司 | 用(R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺及其可药用盐治疗认知障碍 |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| PE20120324A1 (es) * | 2009-05-11 | 2012-04-17 | Envivo Pharmaceuticals Inc | Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos |
| CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
| US8507516B2 (en) | 2009-10-28 | 2013-08-13 | Bristol-Myers Squibb Company | Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| US8278320B2 (en) | 2009-10-28 | 2012-10-02 | Bristol-Myers Squibb Company | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| CN102821814B (zh) | 2009-12-23 | 2015-07-15 | 赛博恩特医疗器械公司 | 用于治疗慢性炎症的神经刺激设备和系统 |
| WO2011137313A1 (en) | 2010-04-30 | 2011-11-03 | Bristol-Myers Squibb Company | Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs |
| KR20180101641A (ko) | 2010-05-17 | 2018-09-12 | 포럼 파마슈티칼즈 인크. | (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태 |
| WO2012154865A2 (en) | 2011-05-09 | 2012-11-15 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| EP3461481A1 (en) | 2012-05-08 | 2019-04-03 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| ES2694299T3 (es) | 2013-02-07 | 2018-12-19 | Heptares Therapeutics Limited | Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4 |
| AU2014282977B2 (en) | 2013-06-21 | 2018-06-14 | Takeda Pharmaceutical Company Limited | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| WO2016126807A1 (en) | 2015-02-03 | 2016-08-11 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| CN108882885A (zh) | 2016-01-20 | 2018-11-23 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| US11745039B2 (en) | 2016-07-25 | 2023-09-05 | Tonal Systems, Inc. | Assisted racking of digital resistance |
| US10661112B2 (en) | 2016-07-25 | 2020-05-26 | Tonal Systems, Inc. | Digital strength training |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
| US10589163B2 (en) | 2017-10-02 | 2020-03-17 | Tonal Systems, Inc. | Exercise machine safety enhancements |
| US10617903B2 (en) | 2017-10-02 | 2020-04-14 | Tonal Systems, Inc. | Exercise machine differential |
| US10486015B2 (en) | 2017-10-02 | 2019-11-26 | Tonal Systems, Inc. | Exercise machine enhancements |
| US10335626B2 (en) | 2017-10-02 | 2019-07-02 | Tonal Systems, Inc. | Exercise machine with pancake motor |
| US11660443B2 (en) | 2018-04-20 | 2023-05-30 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| US12343535B2 (en) | 2019-04-12 | 2025-07-01 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| JP2023512447A (ja) | 2020-01-13 | 2023-03-27 | ザ ファインスタイン インスティチューツ フォー メディカル リサーチ | 脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療 |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
| US11938324B2 (en) | 2020-05-21 | 2024-03-26 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
| US11285355B1 (en) | 2020-06-08 | 2022-03-29 | Tonal Systems, Inc. | Exercise machine enhancements |
| US11998804B2 (en) | 2021-04-27 | 2024-06-04 | Tonal Systems, Inc. | Repetition phase detection |
| US11878204B2 (en) | 2021-04-27 | 2024-01-23 | Tonal Systems, Inc. | First repetition detection |
| US12444497B2 (en) | 2021-05-17 | 2025-10-14 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH601304A5 (es) * | 1974-02-12 | 1978-07-14 | Buskine Sa | |
| US4028351A (en) * | 1971-09-07 | 1977-06-07 | Buskine S.A. | Method for the preparation of derivatives of spiro (4,5)-decane and derivatives thus obtained |
| SU495310A1 (ru) * | 1974-03-05 | 1975-12-15 | Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе | Хинуклидил-3-диарал(гетерил) карбинолы, про вл ющие антигистаминную, антисеротониновую и антиаллергическую активность и способ их получени |
| GB8808433D0 (en) * | 1988-04-11 | 1988-05-11 | Merck Sharp & Dohme | Therapeutic agents |
| GB8816299D0 (en) * | 1988-07-08 | 1988-08-10 | Merck Sharp & Dohme | Therapeutic agents |
| IL97726A (en) * | 1990-04-10 | 1994-12-29 | Israel Inst Biolog Res | Pharmaceutical compositions containing compounds with bridged and unbridged heterocyclic groups, spiro-connected with oxazoline and thiazoline groups, and some new such compounds |
| US5534520A (en) * | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
| US5073560A (en) * | 1990-07-20 | 1991-12-17 | Fisons Corporation | Spiro-isoxazolidine derivatives as cholinergic agents |
| US5137895A (en) * | 1991-04-29 | 1992-08-11 | A. H. Robins Company, Incorporated | 3-[N-aroyl(or thioaroyl)aminomethyl]-3-quinuclidinols |
-
1995
- 1995-08-22 JP JP50799596A patent/JP3708962B2/ja not_active Expired - Fee Related
- 1995-08-22 CN CN95195518A patent/CN1056846C/zh not_active Expired - Fee Related
- 1995-08-22 WO PCT/SE1995/000937 patent/WO1996006098A1/en not_active Ceased
- 1995-08-22 AT AT95930755T patent/ATE192157T1/de not_active IP Right Cessation
- 1995-08-22 BR BR9508751A patent/BR9508751A/pt not_active IP Right Cessation
- 1995-08-22 KR KR1019970701159A patent/KR100366331B1/ko not_active Expired - Fee Related
- 1995-08-22 AU AU34018/95A patent/AU690735B2/en not_active Ceased
- 1995-08-22 PL PL95318760A patent/PL183933B1/pl not_active IP Right Cessation
- 1995-08-22 EP EP95930755A patent/EP0777671B1/en not_active Expired - Lifetime
- 1995-08-22 RU RU97104165A patent/RU2148058C1/ru not_active IP Right Cessation
- 1995-08-22 US US08/525,575 patent/US5902814A/en not_active Expired - Fee Related
- 1995-08-22 HU HU9701965A patent/HUT77352A/hu unknown
- 1995-08-22 SK SK216-97A patent/SK282366B6/sk not_active IP Right Cessation
- 1995-08-22 ES ES95930755T patent/ES2145922T3/es not_active Expired - Lifetime
- 1995-08-22 DE DE69516524T patent/DE69516524T2/de not_active Expired - Fee Related
- 1995-08-22 DK DK95930755T patent/DK0777671T3/da active
- 1995-08-22 CZ CZ1997392A patent/CZ289512B6/cs not_active IP Right Cessation
- 1995-08-22 CA CA002196995A patent/CA2196995C/en not_active Expired - Fee Related
- 1995-08-22 PT PT95930755T patent/PT777671E/pt unknown
- 1995-08-22 NZ NZ292289A patent/NZ292289A/en not_active IP Right Cessation
- 1995-08-22 EE EE9700039A patent/EE03399B1/xx not_active IP Right Cessation
- 1995-08-22 MX MX9701292A patent/MX9701292A/es unknown
- 1995-08-22 UA UA97031329A patent/UA54375C2/uk unknown
- 1995-08-23 IL IL11503995A patent/IL115039A/xx not_active IP Right Cessation
- 1995-08-23 EG EG70395A patent/EG24222A/xx active
- 1995-08-24 TR TR95/01053A patent/TR199501053A2/xx unknown
- 1995-08-24 TW TW084108836A patent/TW397837B/zh not_active IP Right Cessation
- 1995-11-08 SA SA95160370A patent/SA95160370B1/ar unknown
-
1997
- 1997-02-03 IS IS4424A patent/IS1852B/is unknown
- 1997-02-21 NO NO970800A patent/NO307707B1/no not_active IP Right Cessation
- 1997-02-24 FI FI970762A patent/FI112868B/fi active
-
1998
- 1998-11-09 US US09/188,099 patent/US6051581A/en not_active Expired - Fee Related
-
1999
- 1999-11-08 CN CN99123574A patent/CN1099419C/zh not_active Expired - Fee Related
-
2000
- 2000-04-10 AR ARP000101632A patent/AR031828A2/es unknown
- 2000-07-04 GR GR20000401563T patent/GR3033878T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031828A2 (es) | Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia | |
| AR017021A1 (es) | Acido 2-hidroxiacetico | |
| ES2071621T3 (es) | Enantiomero dextrogiro del alfa-(tetrahidro-4,5,6,7-tieno-(3,2-c)-piridil-5)(cloro-2-fenil) acetato de metilo, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen. | |
| GB2071088B (en) | Indane derivatives | |
| ATE229017T1 (de) | Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung | |
| BR0110492A (pt) | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto | |
| AU8794291A (en) | New oxazolopyridine derivatives, processes for preparing these and pharmaceutical compositions containing them | |
| ES8207120A1 (es) | Un procedimiento para la preparacion de nuevos derivados transisomericos de 4-fenil-1,2,3,4-tetrahidro-1-naftalenami-na. | |
| CA2336412A1 (en) | Medicament for treatment of diabetes | |
| DE3586935D1 (de) | Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen. | |
| ES2084339T3 (es) | Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central. | |
| RU94037246A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща | |
| PT649846E (pt) | Derivados da galantamina processo para a sua preparacao e sua utilizacao como medicamentos | |
| JPS5665869A (en) | Novel 22hydroxyalkyll3*4*55trihydroxyypiperidine compound* its manufacture and drug | |
| NO834884L (no) | Fremgangsmaate for fremstilling av farmakologisk aktive nitroalifatiske forbindelser | |
| DE69300453D1 (de) | Isoindolinon-derivat, seine herstellung und dieses enthaltende pharmazeutische zusammen setzungen. | |
| ES2021904A6 (es) | Procedimiento para preparar una composicion farmaceutica a base de un acido piperacinacarboxilico. | |
| DE3787844D1 (de) | Thioester und dessen Verwendung zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von Ischämie und von Reperfusion-Syndromen. | |
| AR008695A1 (es) | Composiciones farmaceuticas estabilizadas, basadas en la asociacion de quinupristina / dalfopristina; procedimiento para prepararlas, utilizacion dedichas composiciones y utilizacion del acido metansulfonico o del acido clorhidrico en la estabilizacion de dichas composiciones. | |
| RU94032285A (ru) | Цефалоспориновые соединения, способ их получения, фармацевтическая композиция | |
| SE9900190D0 (sv) | New compounds | |
| AU532394B2 (en) | Processes | |
| ATE95180T1 (de) | Berbanderivate und ihre herstellung und pharmazeutische zubereitung. | |
| DE3577697D1 (de) | Basische oximether, pharmazeutische mittel gegen angina und die verwendung von basischen oximethern zur herstellung von arzneimitteln zur behandlung von angina. | |
| BR0209163A (pt) | Composto e processos para preparar um composto |